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Abstract
Background: To analyze the potential genetic associations between four polymorphisms of interleukin-6 receptor
(IL-6R) gene and atherosclerotic lipid profiles among young adolescents in Taiwan.
Methods: Using data from the Taipei Children Heart Study-II - a cross-sectional survey in 2003. After multi-stage
sampling, we selected 418 boys and 441 girls with an average age of 13.1 years. We genotyped the subjects for
four IL-6R gene polymorphisms (rs4845617 G/A, rs4845623 A/G, rs8192284 A/C, and rs2229238 C/T) using a TaqMan
5’ nuclease assay. Lipid profiles, including total cholesterol (CHOL), triglycerides (TG), high density lipoprotein-
cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C) were measured using standard methods. We also
calculated CHOL/HDL-C ratio, LDL-C/HDL-C ratio, and TG/HDL-C ratio as atherosclerotic indexes.
Results: IL-6R rs8192284 A/C and rs2229238 C/T variants showed strong associations with high TG (additive model,
OR = 1.58, 95%CI: 1.05-2.37; OR = 1.55, 95%CI: 1.04-2.29, respectively), low HDL-C (additive model, OR = 1.57, 95%CI:
1.03-2.39; OR = 1.68, 95%CI: 1.12-2.52, respectively), and high CHOL/HDL-C (additive model, OR = 1.68, 95%CI: 1.08-
2.61, OR = 1.82, 95%CI: 1.18-2.79, respectively) in girls. We inferred five common haplotypes using rs4845617 G/A,
rs4845623 A/G, and rs2229238 C/T (GAC, GAT, GGC, AAC, and AAT). In girls, the AAT haplotype was associated with
a significant risk of high TG, low HDL-C, high CHOL/HDL-C, and abnormal lipid levels (high TG or low HDL-C) when
compared with the GAC haplotype (OR range = 3.08-4.40, all p < 0.05).
Conclusion: The IL-6R rs8192284 A/C and rs2229238 C/T variants are associated with dyslipidemia in girls, but not
in boys. The AAT haplotype of the IL-6R gene (rs4845617 G/A, rs4845623 A/G, and rs2229238 C/T) may play an
important role in the pathogenesis of dyslipidemia and atherosclerosis in girls.
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Background
Interleukin-6 (IL-6) is a pleiotropic cytokine with impor-
tant roles in both immunoregulation and non-immune
events in a variety of cell types and tissues outside of
the immune system [1]. IL-6 binds to the Interleukin-6
receptor (IL-6R), and together they activate the intracel-
lular signaling cascade leading to the inflammatory
response [2]. Also, IL-6 has been shown to inhibit lipo-
protein lipase activity and stimulate lipolysis, which
affects lipid profiles [3], which could contribute to the
pathogenesis of atherosclerotic disease [4].
The IL-6R gene is located on human chromosome
1q21 [5], a region reported to be linked to dyslipidemia,
metabolic syndrome, and type 2 diabetes [6-8]. In parti-
cular, IL-6R rs8192284 A/C (Asp358Ala), in which the
polymorphism is localized to a functional domain of the
receptor protein [9], was found to correlate with plasma
triglyceride levels [6,8].
However, to our knowledge, the relationship between
genetic variation in the IL-6R gene and lipid profiles has
been rarely investigated in the Asian population, espe-
cially among children or young adolescents. The pur-
poses of this study were to examine possible
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G/A, rs4845623 A/G, rs8192284 A/C, and rs2229238 C/
T) and atherosclerotic lipid profiles among young ado-
lescents in Taiwan.
Methods
Study design and sampling
The Taipei Children Heart Study-II is an epidemiologic
cross-sectional survey aimed at evaluating obesity and
cardiovascular-related diseases risk factors among school
children in Taipei during 2003. In order to obtain a
representative distribution of demographic and lifestyle
characteristics, we conducted a cross-sectional survey of
junior high school students in Taipei. After a multistage
sampling of 85 junior high schools, we randomly
selected 1500 school children for this survey. The sam-
pling method and results have been described elsewhere
[10]. After considering the study power and excluding
missing data, a total of 859 young adolescents (418 boys
and 441 girls) with a mean age of 13.1 years (from 12 to
14) were included in the final analyses.
Data collection
All of the participating young adolescents completed a
structured questionnaire detailing their age, gender,
puberty development and lifestyle characteristics includ-
ing cigarette smoking and alcohol consumption.
Research technicians measured body weight to an accu-
racy of 0.1 kg using a standard beam balance scale with
subjects barefoot and wearing light indoor clothing.
Body height was recorded to the nearest 0.5 cm using a
ruler attached to the scale. Waist circumference (WC)
was measured to the nearest 0.1 cm at the level of the
midpoint between the inferior margin of the last rib and
the iliac crest. Hip circumference was measured at its
widest point to the nearest 0.1 cm. Segmental Bioelectri-
cal Impedance Analysis was applied to measure body fat
percentage to an accuracy of 0.1 percent. The body
mass index for each individual was calculated through
body weight (kg) divided by the square of their height
(m). The Ethical Committee of the Scientific Institute
approved this study and informed consent was obtained
from the parents and the young adolescents.
We measured serum total cholesterol (CHOL) using
the esterase oxidase method [11], triglyceride (TG)
using an enzymatic procedure [12], low density lipopro-
tein-cholesterol (LDL-C) using a multilayer analytical
slide method [13], and high density lipoprotein-choles-
terol (HDL-C) by an enzymatic method with magnesium
precipitation using a Synchron CX5 analyzer (Beckman
Instrument, Palo Alto, CA) [14]. We also calculated
CHOL/HDL-C ratio, LDL-C/HDL-C ratio, and TG/
HDL-C ratio as atherosclerotic indexes. Abnormal lipid
profile criteria and atherosclerotic index ratio were
determined by age- and gender-specific 90
th percentile
(10
th percentile for HDL-C) cut-off points.
SNP genotyping
The genotypes of IL-6R rs4845617 G/A, rs4845623 A/G,
rs8192284 A/C, and rs2229238 C/T were determined by
TaqMan
® assay [15]. Assay on demand TaqMan
® assays
were used for genotyping the SNPs. TaqMan
® probes
and Universal PCR Master Mix were obtained from
Applied Biosystems (Foster City, CA, USA). After ampli-
fication, allele specific fluorescence was measured on
ABI PRISM
® 7900 HT Sequence Detector Systems
(Applied Biosystems, Foster City, CA, USA).
Statistical analyses
The distributions of body height, weight, BMI, waist cir-
cumference, CHOL, TG, HDL-C, LDL-C, CHOL/HDL-
C, LDL-C/HDL-C, and TG/HDL-C with gender specifi-
cation were described by sample means and standard
deviations (SD). The studied children were categorized
into subgroups based on their IL-6R genotypes with
gender specification.
The differences in lipid profiles across IL-6R geno-
types were analyzed by the general linear model (GLM).
To determine if IL-6R SNPs are predictors of lipid pro-
files, a multivariate regression model was applied to
assess the association between IL-6R SNPs and these
profiles after adjusting for age, cigarette smoking, alco-
hol drinking and puberty development.
The SNPs were assessed to see if they were in Hardy-
Weinberg equilibrium using the ALLELE procedure in
SAS/GENETICS release 8.2. We used Haploview soft-
ware to construct haplotype blocks constituted by
“strong LD” markers [16]. The haplotype association
analyses were performed by using the HAPLOTYPE
procedure in SAS/GENETICS release 8.2. A two-tailed p
value less than 0.05 was considered statistically
significant.
All statistical analyses were conducted using the statis-
tical package SAS (SAS Institute Inc, Cary, NC, USA).
Results and Discussion
Distribution of IL-6R gene polymorphisms
The genotype and allele frequencies of IL-6R gene poly-
morphisms are shown in Table 1. The frequencies of
IL-6R rs4845617 G/A genotypes GG, GA and AA were
29.4, 47.6, and 23.0% for boys and 29.5, 47.8, and 22.7%
for girls, respectively. The frequencies of IL-6R
rs4845623 A/G genotypes AA, AG and GG were 69.4,
27.7, and 2.9% for boys and 71.2, 26.1, and 2.7% for
girls, respectively. The frequencies of IL-6R rs8192284
A/C genotypes AA, AC and CC were 38.5, 48.3, and
13.2% for boys and 33.5, 49.0, and 17.5% for girls,
respectively. The frequencies of IL-6R rs2229238 C/T
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13.7% for boys and 35.4, 45.8 and 18.8% for girls,
respectively. There was no significant difference in geno-
type distribution between boys and girls at these four
polymorphisms, and all of them were in Hardy-Wein-
berg equilibrium. IL-6R rs8192284 A/C and rs2229238
C/T each exhibited (marginal) statistically significant dif-
ferences in allele frequency with gender (rs8192284 C
allele, boys vs. girls = 37.3% vs. 42.0%, p = 0.05;
rs2229238 T allele, boys vs. girls = 36.6% vs. 41.7%, p =
0.03, respectively).
Relationship between IL-6R genotypes and lipid profiles
Table 2 shows the relationship between IL-6R genotypes
and lipid profiles of young adolescents with gender
specification. Those are wild-type carriers of IL-6R SNPs
had higher TG levels when compared with boys carrying
the minor genotype (for all IL-6R SNPs p = 0.07, mar-
ginal significance, with the exception of rs4845623 A/
G). In contrast, girls that are minor allele carriers for
rs4845623 A/G had higher HDL-C, and girls that are
minor allele carriers for rs8192284 A/C and rs2229238
had higher CHOL/HDL-C and LDL-C/HDL-C than
those with wild-type genotypes (all p < 0.05).
IL-6R variants and the risk of abnormal lipid profiles
The logistic regression analyses of IL-6R genotypes on
the risk of abnormal lipid profiles and atherosclerotic
indexes in young adolescents after adjusting for age,
cigarette smoking, alcohol drinking, and puberty status
are shown in Table 3. We found significant association
of rs4845617 G/A, rs8192284 A/C, and rs2229238 C/T
variants with high TG in girls (additive model, OR =
1.59, 95%CI: 1.06-2.37; OR = 1.58, 95%CI: 1.05-2.37; OR
= 1.55, 95%CI: 1.04-2.29, respectively). In addition, the
minor alleles of IL-6R rs8192284 A/C and rs2229238 C/
T were associated with low HDL-C (additive model, OR
= 1.57, 95%CI: 1.03-2.39; OR = 1.68, 95%CI: 1.12-2.52,
respectively) and high CHOL/HDL-C (additive model,
OR = 1.68, 95%CI: 1.08-2.61; OR = 1.82, 95%CI: 1.18-
2.79, respectively). The minor allele carriers of
rs8192284 A/C and rs2229238 C/T had a greater risk of
high TG (OR = 2.21, 95%CI: 1.10-4.44; OR = 2.14, 95%
CI: 1.09-4.20, respectively), low HDL-C (OR = 1.98, 95%
CI: 0.99-4.00; OR = 2.16, 95%CI: 1.07-4.35, respectively),
and high CHOL/HDL-C (OR = 3.17, 95%CI: 1.37-7.30;
OR = 3.47, 95%CI: 1.51-8.00, respectively) than wild-
type girls in recessive model analyses. However, lipid
status in boys was not significantly associated with IL-
6R polymorphisms.
Haplotype analyses of IL-6R gene polymorphisms on the
risk of abnormal lipid profiles
Table 4 shows the haplotype frequencies of the IL-6R
gene and their association with abnormal lipid profiles
and atherosclerotic indexes. We inferred the haplotypes
from the polymorphisms within the linkage disequili-
brium block (including IL-6R rs4845617 G/A, rs4845623
A/G, rs8192284 A/C, and rs2229238 C/T). Because
rs8192284 A/C and rs2229238 C/T were almost in link-
age disequilibrium (r
2>0.9), only rs2229238 C/T was
kept in the haplotype inference, together with the other
two SNPs (rs4845617 G/A, rs4845623 A/G) in this link-
age disequilibrium block (Figure 1.). Five common hap-
lotypes (frequency >5%) were identified (H1: GAC, H2:
GAT, H3: GGC, H4: AAC, H5: AAT) with the three
SNPs (rs4845617 G/A - rs4845623 A/G - rs2229238 C/
T). Haplotype H5 had a significant risk of high TG, low
HDL-C, high CHOL/HDL-C, and abnormal lipid levels
Table 1 The genotypes and alleles frequencies of IL-6R
gene polymorphisms among young adolescents in
Taiwan
Boys (n = 418) Girls (n = 441) c
2 test
n % n % p value
rs4845617 G/A
Genotype
GG 123 29.4 130 29.5 0.99
GA 199 47.6 211 47.8
AA 96 23.0 100 22.7
Allele
G 445 53.2 471 53.4 0.94
A 391 46.8 411 46.6
rs4845623 A/G
Genotype
AA 290 69.4 314 71.2 0.84
AG 116 27.7 115 26.1
GG 12 2.9 12 2.7
Allele
A 696 83.2 743 84.2 0.58
G 140 16.8 139 15.8
rs8192284 A/C
Genotype
AA 161 38.5 148 33.5 0.13
AC 202 48.3 216 49.0
CC 55 13.2 77 17.5
Allele
A 524 62.7 512 58.0 0.05
C 312 37.3 370 42.0
rs2229238 C/T
Genotype
CC 169 40.4 156 35.4 0.08
CT 192 45.9 202 45.8
TT 57 13.7 83 18.8
Allele
C 530 63.4 514 58.3 0.03
T 306 36.6 368 41.7
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Wild-type Heterozygotes Minor-type
mean ± s.d. mean ± s.d. mean ± s.d. p
a
Boys (n = 418)
rs4845617 G/A GG (n = 123) GA (n = 199) AA (n = 96)
CHOL (mg/dl) 158.7 ± 25.9 161.4 ± 28.4 156.7 ± 25.4 0.71
TG (mg/dl) 70.1 ± 29.9 70.2 ± 34.4 63.5 ± 31.3 0.07
HDL-C (mg/dl) 49.0 ± 11.0 50.7 ± 11.7 48.8 ± 12.0 0.95
LDL-C (mg/dl) 80.5 ± 18.2 81.7 ± 19.6 80.6 ± 19.7 0.84
CHOL/HDL-C 3.38 ± 0.84 3.32 ± 0.85 3.39 ± 1.01 0.85
LDL-C/HDL-C 1.73 ± 0.57 1.70 ± 0.95 1.77 ± 0.69 0.89
TG/HDL-C 1.57 ± 0.94 1.52 ± 1.02 1.47 ± 1.08 0.18
rs4845623 A/G AA (n = 290) AG (n = 116) GG (n = 12)
CHOL (mg/dl) 160.0 ± 27.2 158.8 ± 26.8 155.3 ± 26.0 0.51
TG (mg/dl) 68.0 ± 32.0 71.1 ± 33.8 59.3 ± 30.1 0.87
HDL-C (mg/dl) 49.7 ± 11.6 49.3 ± 11.4 56.7 ± 11.3 0.44
LDL-C (mg/dl) 81.8 ± 19.2 80.4 ± 19.4 72.0 ± 16.5 0.12
CHOL/HDL-C 3.36 ± 0.86 3.38 ± 0.96 2.80 ± 0.48 0.24
LDL-C/HDL-C 1.74 ± 0.59 1.73 ± 0.65 1.31 ± 0.36 0.09
TG/HDL-C 1.51 ± 0.98 1.61 ± 1.11 1.05 ± 0.46 0.84
rs8192284 A/C AA (n = 161) AC (n = 202) CC (n = 55)
CHOL (mg/dl) 158.8 ± 28.6 159.6 ± 26.0 161.3 ± 25.9 0.64
TG (mg/dl) 69.9 ± 33.5 70.3 ± 33.8 58.7 ± 21.2 0.07
HDL-C (mg/dl) 48.9 ± 10.6 50.2 ± 12.5 50.6 ± 10.7 0.22
LDL-C (mg/dl) 80.4 ± 20.2 80.9 ± 18.7 83.9 ± 18.2 0.37
CHOL/HDL-C 3.38 ± 0.89 3.35 ± 0.93 3.28 ± 0.71 0.46
LDL-C/HDL-C 1.73 ± 0.60 1.73 ± 0.64 1.72 ± 0.51 0.93
TG/HDL-C 1.57 ± 1.05 1.56 ± 1.05 1.24 ± 0.62 0.06
rs2229238 C/T CC (n = 169) CT (n = 192) TT (n = 57)
CHOL (mg/dl) 158.3 ± 28.9 160.0 ± 25.7 161.2 ± 25.6 0.51
TG (mg/dl) 70.2 ± 33.3 70.0 ± 34.1 59.5 ± 21.5 0.07
HDL-C (mg/dl) 49.3 ± 10.9 50.1 ± 12.3 50.1 ± 11.0 0.49
LDL-C (mg/dl) 79.7 ± 20.7 81.5 ± 18.1 84.0 ± 18.4 0.17
CHOL/HDL-C 3.35 ± 0.90 3.36 ± 0.91 3.33 ± 0.78 0.96
LDL-C/HDL-C 1.71 ± 0.61 1.74 ± 0.62 1.75 ± 0.57 0.47
TG/HDL-C 1.57 ± 1.04 1.56 ± 1.06 1.27 ± 0.63 0.09
Girls (n = 441)
rs4845617 G/A GG (n = 130) GA (n = 211) AA (n = 100)
CHOL (mg/dl) 167.1 ± 26.0 168.7 ± 28.5 169.8 ± 28.2 0.47
TG (mg/dl) 66.8 ± 27.0 69.6 ± 31.0 74.0 ± 32.1 0.11
HDL-C (mg/dl) 51.7 ± 11.2 52.5 ± 12.2 49.9 ± 10.3 0.31
LDL-C (mg/dl) 85.3 ± 18.3 86.7 ± 21.0 87.4 ± 20.6 0.44
CHOL/HDL-C 3.33 ± 0.70 3.36 ± 0.89 3.52 ± 0.80 0.16
LDL-C/HDL-C 1.72 ± 0.50 1.74 ± 0.60 1.82 ± 0.55 0.26
TG/HDL-C 1.37 ± 0.72 1.47 ± 1.01 1.59 ± 0.96 0.09
rs4845623 A/G AA (n = 314) AG (n = 115) GG (n = 12)
CHOL (mg/dl) 167.3 ± 27.9 170.5 ± 27.3 178.4 ± 23.7 0.17
TG (mg/dl) 71.1 ± 31.7 67.5 ± 26.8 58.4 ± 15.3 0.24
HDL-C (mg/dl) 50.7 ± 11.0 54.2 ± 12.8 51.7 ± 10.0 0.04
LDL-C (mg/dl) 86.0 ± 20.7 86.8 ± 18.9 93.1 ± 14.2 0.44
CHOL/HDL-C 3.43 ± 0.85 3.27 ± 0.73 3.54 ± 0.63 0.37
LDL-C/HDL-C 1.78 ± 0.58 1.68 ± 0.51 1.87 ± 0.46 0.52
TG/HDL-C 1.53 ± 1.01 1.34 ± 0.66 1.17 ± 0.40 0.07
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lotype H1 in girls (OR = 3.08, 95%CI: 1.07-8.87; OR =
3.30, 95%CI: 1.11-9.85; OR = 4.40, 95%CI: 1.35-14.32;
and OR = 3.22, 95%CI: 1.34-7.76, respectively). How-
ever, there was still no significant association of abnor-
mal lipid profiles with IL-6R haplotypes in boys.
Discussion
In this study, the minor allele of IL-6R rs8192284 A/C
and IL-6R rs2229238 C/T variants were associated with
a higher risk of abnormal lipid profiles in girls. The girls
w i t ht h eA A Th a p l o t y p eo ft h eI L - 6 Rg e n e( r s 4 8 4 5 6 1 7
G/A, rs4845623 A/G, and rs2229238 C/T) had signifi-
cant risk of high TG, low HDL-C, high CHOL/HDL-C,
and abnormal lipid levels (high TG or low HDL-C).
However, there was almost no statistical association
between IL-6R variants and lipid profiles in boys.
IL-6 binds to its receptor (IL-6R), and together they
activate the intracellular signaling cascade leading to the
inflammatory response [17]. Previous studies have
reported that IL-6 is associated with lipid metabolism
[3,18]. It is involved in production of TG, decreases lipo-
protein lipase activity and monomeric lipoprotein lipase
in plasma, which contributes to increased macrophage
uptake of lipids. In atheromatous plaques and fatty
streaks, smooth muscle cells and macrophage foam cells
express IL-6, may be an important role for this cytokine
in the progression of atherosclerosis [4]. Some studies
have indicated that elevated TG may correlate with IL-6R
gene polymorphisms [6,8]. Our data reveals that there is
a borderline association of the major allele (the A allele)
of IL-6R rs8192284 A/C and increased TG levels in boys,
which is similar to other findings [6,8]. In contrast, the
minor alleles of the IL-6R SNPs were related to high dys-
lipidemia risk in girls. The relationship between IL-6R
rs8192284 A/C variants and high TG risk was inconsis-
tent with previous findings [6,8]. In Spain, a study of
middle-aged Caucasians indicated that carriers of the A
allele of the IL-6R rs8192284 A/C polymorphism had
higher plasma TG levels than those with the CC geno-
type [6]. In the Guangzhou Biobank Cohort Study-Cardi-
ovascular Disease (GBCS-CVD) sub-cohort study, the A
allele of IL-6R rs8192284 A/C also was associated with
increased TG levels among aged Chinese [8].
The possible reasons for inconsistent results in girls
a r ea sf o l l o w s .F i r s t ,t h e r eis strong evidence that IL-6
levels increase with age [19], and some studies have
evaluated alterations in the frequency of IL-6 SNPs with
age [20,21]. Moreover, IL-6 and insulin action have had
conflicting results in different tissues (organs), such as
adipose tissue, skeletal muscle, and liver [22]. IL-6 and
lipid metabolism might potentially contribute to differ-
ent adipose or skeletal muscle distribution in children
and adults. Our study was focused on children, so the
subjects were younger than in the Spanish and GBCS-
CVD studies (mean ages 43.3 and 59.4 years, respec-
tively). We suggest that differences in the frequencies of
genotypes or alleles may, in part, be responsible for the
discrepancies in the results of these studies, but that age
differences between the populations should also be
taken into consideration. Secondly, previous studies
have shown that there are gender differences in IL-6
production [23], therefore IL-6 or IL-6R polymorphisms
modifying IL-6 levels might potentially contribute to sex
disparity. In IL-6 polymorphisms, females with the CC
genotype of IL-6 -174 G/C have an earlier onset of type
Table 2 The lipid profiles among young adolescents with different IL-6R genotypes (Continued)
rs8192284 A/C AA (n = 148) AC (n = 216) CC (n = 77)
CHOL (mg/dl) 166.8 ± 26.9 168.6 ± 27.6 171.4 ± 29.3 0.21
TG (mg/dl) 66.6 ± 24.8 70.5 ± 30.3 73.9 ± 38.0 0.24
HDL-C (mg/dl) 52.8 ± 11.7 51.6 ± 11.8 49.8 ± 10.2 0.09
LDL-C (mg/dl) 84.7 ± 18.7 86.7 ± 20.9 89.2 ± 20.3 0.11
CHOL/HDL-C 3.26 ± 0.66 3.42 ± 0.90 3.56 ± 0.84 0.01
LDL-C/HDL-C 1.67 ± 0.48 1.77 ± 0.61 1.86 ± 0.54 0.02
TG/HDL-C 1.34 ± 0.61 1.51 ± 0.99 1.62 ± 1.18 0.10
rs2229238 C/T CC (n = 156) CT (n = 202) TT (n = 83)
CHOL (mg/dl) 166.7 ± 27.2 168.6 ± 27.0 171.5 ± 30.2 0.17
TG (mg/dl) 66.3 ± 24.6 70.9 ± 30.9 73.6 ± 36.9 0.16
HDL-C (mg/dl) 52.9 ± 11.9 51.5 ± 11.7 49.8 ± 10.4 0.07
LDL-C (mg/dl) 84.5 ± 18.9 86.7 ± 20.8 89.2 ± 20.5 0.08
CHOL/HDL-C 3.25 ± 0.66 3.43 ± 0.90 3.56 ± 0.84 0.008
LDL-C/HDL-C 1.66 ± 0.48 1.78 ± 0.61 1.86 ± 0.54 0.01
TG/HDL-C 1.33 ± 0.61 1.52 ± 1.01 1.61 ± 1.15 0.06
Abbreviation: CHOL, Cholesterol; TG, Triglycerides; HDL-C, High density lipoprotein-cholesterol; LDL-C, Low density lipoprotein-cholesterol.
a Using GLM test after adjusting for age, cigarette smoking, alcohol drinking, and puberty status.
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females and all males [24]. Of studies focused on IL-6R
polymorphisms, some have analyzed females (in relation
to IL-6 levels, CRP levels, bone mineral density, obesity,
hyperandrogenism, preterm birth, type 2 diabetes, and
melanoma) [25-32], and another concentrated on males
(studying the relationship between IL-6R polymorphisms
and obesity) [33]. Most analyses of IL-6R SNPs have not
investigated (or at least have not reported) gender differ-
ences. We found that there was no gender difference in
IL-6R rs8192284 A/C genotype frequency distribution,
but that there was a borderline significant disparity in
allele frequency distribution, which is similar to recent
studies [33,34]. In addition, previous studies have found
that estrogen modulation and the inherently greater
amount of adipose tissue in females relative to males
may be responsible for the observed differences in IL-6
production [35]. Our data show that a relationship
between IL-6R SNPs and lipid status is almost only
observed in girls, for both genotype and haplotype ana-
lyses. The IL-6R genotype or allele distribution of differ-
ent genders may be responsible for these results. The
gender-specific role of IL-6R SNPs in the pathology of
dyslipidemia should be further investigated.
Table 3 Logistic regression analyses of different IL-6R genotypes on lipid status among young adolescents
a
Model type rs4845617 G/A rs4845623 A/G rs8192284 A/C rs2229238 C/T
OR 95%CI OR 95%CI OR 95%CI OR 95%CI
Boys
High CHOL additive 0.91 0.55-1.50 1.10 0.58-2.06 0.90 0.53-1.52 0.81 0.48-1.36
dominant 0.74 0.29-1.86 0.77 0.09-6.39 1.36 0.53-3.50 1.32 0.51-3.38
recessive 1.01 0.46-2.19 1.18 0.56-2.47 0.70 0.35-1.42 0.58 0.29-1.17
High TG additive 0.92 0.61-1.40 1.45 0.85-2.46 0.85 0.54-1.34 0.81 0.51-1.27
dominant 0.95 0.46-1.97 1.56 0.32-7.50 0.39 0.12-1.32 0.38 0.11-1.26
recessive 0.86 0.45-1.63 1.55 0.83-2.91 1.04 0.56-1.94 0.95 0.52-1.75
High HDL-C additive 1.02 0.70-1.49 0.98 0.58-1.64 0.78 0.51-1.18 0.84 0.56-1.27
dominant 1.35 0.72-2.52 0.51 0.06-4.04 0.68 0.28-1.68 0.79 0.34-1.85
recessive 0.81 0.45-1.45 1.04 0.58-1.89 0.74 0.43-1.28 0.81 0.46-1.40
High LDL-C additive 0.78 0.49-1.26 0.81 0.42-1.57 0.83 0.50-1.39 0.81 0.49-1.34
dominant 0.94 0.41-2.15 - - 1.22 0.48-3.09 1.18 0.46-2.97
recessive 0.60 0.30-1.21 0.90 0.43-1.90 0.65 0.33-1.27 0.62 0.32-1.22
High CHOL/HDL-C additive 1.24 0.79-1.93 0.74 0.38-1.43 0.70 0.43-1.16 0.78 0.48-1.27
dominant 1.39 0.67-2.89 - - 0.30 0.07-1.26 0.45 0.13-1.51
recessive 1.28 0.61-2.66 0.81 0.39-1.67 0.79 0.41-1.51 0.86 0.45-1.64
Girls
High CHOL additive 1.23 0.79-1.93 0.96 0.51-1.79 1.13 0.71-1.80 1.20 0.77-1.88
dominant 1.15 0.55-2.43 1.78 0.36-8.79 1.51 0.70-3.27 1.60 0.76-3.38
recessive 1.55 0.71-3.36 0.85 0.41-1.78 0.97 0.49-1.92 1.07 0.54-2.12
High TG additive 1.59 1.06-2.37 0.57 0.30-1.09 1.58 1.05-2.37 1.55 1.04-2.29
dominant 1.77 0.95-3.28 - - 1.53 0.77-3.02 1.54 0.79-2.99
recessive 2.00 0.97-4.11 0.59 0.29-1.19 2.21 1.10-4.44 2.14 1.09-4.20
High HDL-C additive 1.24 0.83-1.86 0.76 0.41-1.41 1.57 1.03-2.39 1.68 1.12-2.52
dominant 1.24 0.64-2.41 0.73 0.09-5.94 1.67 0.84-3.32 1.90 0.98-3.67
recessive 1.46 0.74-2.92 0.74 0.37-1.46 1.98 0.99-4.00 2.16 1.07-4.35
High LDL-C additive 1.08 0.70-1.65 1.01 0.56-1.82 1.10 0.71-1.71 1.22 0.80-1.86
dominant 0.87 0.41-1.84 0.75 0.09-6.08 0.77 0.33-1.82 0.99 0.45-2.16
recessive 1.38 0.68-2.83 1.05 0.53-2.05 1.48 0.74-2.96 1.63 0.81-3.25
High CHOL/HDL-C additive 1.27 0.83-1.94 0.70 0.37-1.36 1.68 1.08-2.61 1.82 1.18-2.79
dominant 1.38 0.69-2.75 1.75 0.36-8.56 1.35 0.64-2.86 1.61 0.79-3.27
recessive 1.38 0.68-2.82 0.57 0.27-1.22 3.17 1.37-7.30 3.47 1.51-8.00
Abbreviation: CHOL, Cholesterol; TG, Triglycerides; HDL-C, High density lipoprotein-cholesterol; LDL-C, Low density lipoprotein-cholesterol.
additive model: major-homozygotes v.s. heterozygotes v.s. minor-homozygotes, reference group: major-homozygotes.
dominant model: major-homozygotes/heterozygotes v.s. minor-homozygotes, reference group: major-homozygotes/heterozygotes.
recessive model: major-homozygotes v.s. heterozygotes/minor-homozygotes; reference group: major-homozygotes.
a All abnormal variables defined as age- and gender-specific 90
th percentile cut-off point of study variables and OR was adjusted for age, cigarette smoking,
alcohol drinking, and puberty status.
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Page 6 of 9Table 4 Haplotype frequencies of IL-6R gene and associated with lipid status among young adolescents
a
Haplotype
b Abnormal Normal OR 95%CI p Global p
HF HF
Boys
High TG H1 0.35 0.33 1.00 - - 0.75
H2 0.08 0.10 0.49 0.08-2.84 0.43
H3 0.13 0.10 1.27 0.27-5.91 0.76
H4 0.13 0.14 0.68 0.15-2.98 0.61
H5 0.24 0.27 0.61 0.20-1.90 0.39
Low HDL-C H1 0.39 0.32 1.00 - - 0.29
H2 0.07 0.10 0.31 0.06-1.60 0.16
H3 0.07 0.11 0.23 0.04-1.18 0.08
H4 0.13 0.14 0.47 0.13-1.78 0.27
H5 0.24 0.27 0.51 0.18-1.38 0.18
Abnormal lipid
c H1 0.36 0.32 1.00 - - 0.84
H2 0.09 0.10 0.64 0.17-2.41 0.51
H3 0.09 0.11 0.55 0.14-2.10 0.38
H4 0.14 0.14 0.68 0.21-2.18 0.51
H5 0.24 0.27 0.64 0.26-1.57 0.33
High CHOL/HDL-C H1 0.37 0.33 1.00 - - 0.19
H2 0.06 0.10 0.27 0.03-2.29 0.23
H3 0.05 0.11 0.16 0.02-1.45 0.10
H4 0.19 0.14 1.26 0.32-5.02 0.74
H5 0.25 0.27 0.63 0.19-2.05 0.44
Girls
High TG H1 0.21 0.30 1.00 - - 0.04
H2 0.16 0.13 2.75 0.62-12.26 0.19
H3 0.06 0.12 0.47 0.06-3.64 0.47
H4 0.17 0.13 3.22 0.68-15.36 0.14
H5 0.36 0.28 3.08 1.07-8.87 0.04
Low HDL-C H1 0.22 0.30 1.00 - - 0.13
H2 0.17 0.12 3.56 0.81-15.53 0.09
H3 0.09 0.11 1.35 0.23-8.04 0.74
H4 0.12 0.14 1.45 0.24-8.81 0.69
H5 0.37 0.28 3.30 1.11-9.85 0.03
Abnormal lipid H1 0.22 0.31 1.00 - - 0.03
H2 0.16 0.12 2.93 0.85-10.03 0.09
H3 0.08 0.12 0.91 0.20-4.07 0.90
H4 0.15 0.13 2.57 0.67-9.85 0.17
H5 0.36 0.27 3.22 1.34-7.76 0.009
High CHOL/HDL-C H1 0.21 0.30 1.00 - - 0.08
H2 0.17 0.12 4.66 0.97-22.38 0.05
H3 0.10 0.11 2.05 0.32-13.28 0.45
H4 0.11 0.14 1.97 0.29-13.46 0.49
H5 0.38 0.28 4.40 1.35-14.32 0.01
Abbreviation: CHOL, Cholesterol; TG, Triglycerides; HDL-C, High density lipoprotein-cholesterol; LDL-C, Low density lipoprotein-cholesterol; HF, Haplotype
frequency
a All abnormal variables defined as age- and gender-specific 90
th percentile cut-off point of study variables
b Five common haplotype frequencies of IL-6R rs4845617 G/A, rs4845623 A/G, and rs2229238 C/T (H1: GAC, H2: GAT, H3: GGC, H5: AAC, H6: AAT) at least 5% and
H1 as reference group.
c Abnormal lipid includes high TG or low HDL-C
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to identify disease associations because they reflect com-
plete gene structure. IL-6R rs8192284 A/C is a well-
known functional polymorphism in exon 9 of the IL-6R
gene which results in an amino acid substitution
(Asp358Ala) [36]. After calculations using Haploview
software, we determined that rs8192284 A/C and
rs2229238 C/T were almost in LD (LD = 0.97, r
2 =
0.91). The LD was similar to that calculated for
rs2228145 G/T (corresponding to Asp358Ala substitu-
tion) and rs2229238 C/T in a Pima Indian study (LD =
0.98, r
2 = 0.78) [37]. Using Haploview, we picked
rs4845617 G/A, rs4845623 A/G, and rs2229238 C/T for
haplotype analysis. We found that carriers of the AAT
haplotype had a significantly greater risk of dyslipidemia
than carriers of the major allele haplotype (GAC). The
results indicate that haplotype analysis can indicate a
higher dyslipidemia risk than single polymorphism ana-
lysis. The haplotype effects within the IL-6R SNPs might
explain the discrepancies between our results and pre-
vious studies, which examined SNPs separately. Further
studies might explore how IL-6R haplotype influences
lipid profiles.
Several limitations of our study should be noted. First,
we did not control the potential confounders of food
intake and physical activity. These factors correlate with
plasma lipids and IL-6 levels [38], so that may affect IL-
6R gene expression and disturb the regulation of IL-6
and lipid metabolism. In an adult population, a similar
study of IL-6R SNPs and lipid profiles may yield biased
or confounded results if subjects are on a special diet,
exercise, or are being treated for lipid-related disorders,
which may also alter lipid levels. However, children of
these age groups are rarely on special diets, exercise, or
treatment regimens for dyslipidemia. Secondly, the mea-
surement errors in assessing the biological variables of
lipid profiles are likely to be minimal. Any error is likely
to be random and only attenuate our results. Thirdly,
the sample size limits the statistical power of this study.
We may not confirm absolutely which SNP is the real
functional variant, nor rule out the possibility of minor
variants within our SNPs. Moreover, we did not detect
serum levels of IL-6 to investigate the relationship
between the IL-6R SNPs and the serum level of IL-6.
We could not observe a direct association between the
IL-6 levels and lipid profiles for IL-6R variants. In the
future, may be worth investigating possible associations
between IL-6R SNPs and serum levels of IL-6 or sIL-6R
in children.
The notable findings of our study were that the IL-6R
rs4845617 G/A, rs4845623 A/G, and 2229238 C/T poly-
morphic markers were chosen to construct the haplo-
type, which differed from that used in previous studies,
and that they showed a significant association with lipid
status. This is also the first study to investigate the rela-
tionship between IL-6R SNPs and lipid profiles in young
adolescents. Many biological processes and different tis-
sues contribute to circulating IL-6 levels. If the IL-6R
gene polymorphisms relate to IL-6 and lipid metabolism,
they could be used as stable biological markers to detect
lipid-related disorders and be very helpful for the pre-
vention of these diseases.
Conclusions
In summary, IL-6R rs8192284 A/C and rs2229238 C/T
variants associated with dyslipidemia were presented
among young adolescents, especially in girls, in Taiwan.
The AAT haplotype of IL-6R gene SNPs rs4845617 G/
A, rs4845623 A/G, and rs2229238 C/T may play an
important role in the pathogenesis of dyslipidemia and
atherosclerosis in girls. Further mechanistic studies are
warranted to explore how IL-6R SNPs exert their effect
on lipid metabolism. This information may suggest ways
of tailoring strategies for the prevention of dyslipidemia
and atherosclerosis according to the genetic make-up of
each individual patient.
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